These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38592132)

  • 1. Arrhythmias and Device Therapies in Cardiac Amyloidosis.
    Bukhari S; Khan SZ; Ghoweba M; Khan B; Bashir Z
    J Clin Med; 2024 Feb; 13(5):. PubMed ID: 38592132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of ventricular arrhythmias and role of implantable cardioverter-defibrillator in cardiac amyloidosis.
    Bukhari S; Khan B
    J Cardiol; 2023 May; 81(5):429-433. PubMed ID: 36894119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Arrhythmias in Cardiac Amyloidosis.
    Giancaterino S; Urey MA; Darden D; Hsu JC
    JACC Clin Electrophysiol; 2020 Apr; 6(4):351-361. PubMed ID: 32327068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arrhythmias in Cardiac Amyloidosis: Challenges in Risk Stratification and Treatment.
    Cheung CC; Roston TM; Andrade JG; Bennett MT; Davis MK
    Can J Cardiol; 2020 Mar; 36(3):416-423. PubMed ID: 32145868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Arrhythmias in Cardiac Amyloidosis and Cardiac Sarcoidosis.
    Ashraf I; Peck MM; Maram R; Mohamed A; Ochoa Crespo D; Kaur G; Malik BH
    Cureus; 2020 Aug; 12(8):e9842. PubMed ID: 32953349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator.
    Kim EJ; Holmes BB; Huang S; Lugo R; Al Aboud A; Goodman S; Hung RR; Slosky D; Stevenson WG; Michaud GF; John RM
    Europace; 2020 Aug; 22(8):1216-1223. PubMed ID: 32514579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biventricular pacing (cardiac resynchronization therapy): an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(13):1-60. PubMed ID: 23074464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Arrhythmia, device interventions and mortality analysis in patients with implanted cardioverter-defibrillator with/without resynchronisation therapy in dilative cardiomyopathy in primary prevention of sudden cardiac death].
    Lelakowski J; Pudło J; Lelakowska-Pieła M; Rydlewska A; Piekarz J; Domaracki D
    Pol Merkur Lekarski; 2016 Apr; 40(238):216-22. PubMed ID: 27137820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventional electrophysiology and its role in the treatment of cardiac arrhythmia.
    Teo WS; Kam R; Tan A
    Ann Acad Med Singap; 1998 Mar; 27(2):248-54. PubMed ID: 9663319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Implantable Electronic Devices: A Window Into the Evolution of Conduction Disease in Cardiac Amyloidosis.
    Rehorn MR; Loungani RS; Black-Maier E; Coniglio AC; Karra R; Pokorney SD; Khouri MG
    JACC Clin Electrophysiol; 2020 Sep; 6(9):1144-1154. PubMed ID: 32972550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.
    Kristen AV; Dengler TJ; Hegenbart U; Schonland SO; Goldschmidt H; Sack FU; Voss F; Becker R; Katus HA; Bauer A
    Heart Rhythm; 2008 Feb; 5(2):235-40. PubMed ID: 18242546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
    Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K
    ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ventricular arrhythmia burden and implantable cardioverter-defibrillator outcomes in transthyretin cardiac amyloidosis.
    Brown MT; Yalamanchili S; Evans ST; Ram P; Blank EA; Lyle MA; Merchant FM; Bhatt KN
    Pacing Clin Electrophysiol; 2022 Apr; 45(4):443-451. PubMed ID: 35257420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophysiological Manifestations of Cardiac Amyloidosis:
    Hartnett J; Jaber W; Maurer M; Sperry B; Hanna M; Collier P; Patel DR; Wazni OM; Donnellan E
    JACC CardioOncol; 2021 Oct; 3(4):506-515. PubMed ID: 34729522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiac arrhythmias and amyloidosis].
    Salinas-Arce J; Alca-Clares R; Gonzales-Luna AC; Cabrera-Saldaña M; Mendoza-Novoa P; Solórzano-Altamirano P; Guevara-Valdivia M
    Arch Peru Cardiol Cir Cardiovasc; 2022; 3(2):82-97. PubMed ID: 37351307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHA
    Kavsur R; Becher MU; Nassan W; Sedaghat A; Aksoy A; Schrickel JW; Nickenig G; Tiyerili V
    Int J Cardiol Heart Vasc; 2021 Jun; 34():100802. PubMed ID: 34095451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis.
    Patel KS; Hawkins PN; Whelan CJ; Gillmore JD
    BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25535224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-specific aspects of management of cardiac arrhythmias in patients with muscular dystrophies.
    Majewski J; Varma M; Davis G; Lelakowski J
    Pol Merkur Lekarski; 2019 Oct; 47(280):153-156. PubMed ID: 31760399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.